Translational Oncology · 2011 · 26 citations · 28 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingHer2-positive Breast CancerHormonal TherapyTargeted Cancer TherapyTargeted TherapyTyrosine Kinase InhibitorsBreast Cancer Endocrine TherapyBreast Cancer ProgressionEpidermal Growth Factor Receptor InhibitionEpidermal Growth Factor Receptor SignalingEstrogen Receptor SignalingHer2 InhibitorsMitogen-activated Protein Kinase SignalingTyrosine Kinase Inhibitor Therapy
The estrogen receptor (ER) pathway and the epidermal growth factor receptor (EGFR) pathway play pivotal roles in breast cancer progression. Targeted therapies able to intercept ER or signaling downstream to EGFR and its kin, HER2, are routinely used to treat distinct groups of breast cancer patients. However, patient responses are limited by resistance to endocrine therapy, which may be due to compensatory HER2/EGFR signaling. This raises the possibility that simultaneous interception of HER2 and ER may enhance therapeutic efficacy. To address the question, we treated breast cancer cells with both fulvestrant (ICI 182780), an ER antagonist with no agonist effects, and lapatinib, an orally available tyrosine kinase inhibitor specific to EGFR and HER2. Our results indicate that the combination of drugs is especially effective when applied to HER2-overexpressing, ER-positive cancer cells. Interestingly, fulvestrant activated the mitogen-activated protein kinase (MAPK) pathway of these cells, but complete inhibition of MAPK signaling was observed on cotreatment with lapatinib. Taken together, our observations reinforce the possibility that the effectiveness of combining anti-ER and anti-HER2/EGFR drugs may be especially effective on a relatively small subtype of HER2-overexpressing, ER-positive tumors of the breast.
28
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations
Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations
Medicine, Oncology, Pharmacology +17
Stephen Johnston, John Pippen, Xavier Pivot et al. · Journal of Clinical Oncology · 2009 · 1K citations · Full text
Medicine, Oncology, Pharmacology +17
Bella Kaufman, John R. Mackey, Michael Clemens et al. · Journal of Clinical Oncology · 2009 · 850 citations · Full text
Medicine, Oncology, Pharmacotherapy +17